Among these small molecule inhibitors, several synthetic small molecules from Bristol Myers Squibb (e.g. BMS1166 and BMS202) and Curis Inc. (i.e. CA-170) exhibit promising tumor suppression effects in interrupting the PD-1/PD-L1 interactions [43, 44]. This evidence concerns the gene CD274 and neoplasm.